Q3 2020 Sales Performance
Consumer Healthcare: revenue breakdown 2019
Revenues of £9.0bn (+17% CER, +2% Pro-forma), including 5 months of Pfizer sales
Categories
Skin Health (+7%)
Nutrition (+81%)
£1.2bn
(13%)
£0.6bn
(7%)
£2.7bn
(30%)
Oral Health (+7%)
£4.5bn
(50%)
Wellness (+14%)
Regions
gsk
US (+36%)
Europe (+6%)
£2.6bn
£2.5bn
(29%)
(27%)
£4.0bn
(44%)
International (+14%)
Source: GSK Full year 2019 results release - February 2020
All growths at constant exchange rates (CER). Breakdown percentages are approximate
CER growth rates include five months' results of former Pfizer consumer healthcare business. Pro-forma CER growth rates are calculated as if the equivalent five months of Pfizer
consumer healthcare business results, as reported by Pfizer, were included in the comparative period of 2018.
75View entire presentation